InMode Ltd. (NASDAQ:INMD) Stake Raised by Systematic Financial Management LP

Systematic Financial Management LP increased its stake in InMode Ltd. (NASDAQ:INMD - Free Report) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,026,823 shares of the healthcare company's stock after purchasing an additional 44,712 shares during the period. Systematic Financial Management LP owned 1.48% of InMode worth $17,148,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of InMode during the fourth quarter worth $87,000. Farther Finance Advisors LLC increased its stake in InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after purchasing an additional 1,154 shares during the period. Covestor Ltd increased its stake in shares of InMode by 13.9% during the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after buying an additional 723 shares during the period. Lazard Asset Management LLC increased its stake in InMode by 6,128.7% in the fourth quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock valued at $105,000 after purchasing an additional 6,190 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in InMode in the fourth quarter valued at approximately $114,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on INMD. UBS Group cut their price objective on InMode from $19.00 to $16.25 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Baird R W cut InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Jefferies Financial Group cut their price objective on InMode from $16.00 to $15.00 and set a "hold" rating for the company in a research report on Monday, April 14th. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research report on Monday, April 28th. Finally, Barclays dropped their price target on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $18.54.

InMode Stock Performance

Shares of NASDAQ:INMD traded up $0.23 on Thursday, hitting $14.44. The company's stock had a trading volume of 478,129 shares, compared to its average volume of 1,186,363. The stock's 50-day moving average is $15.77 and its two-hundred day moving average is $17.28. InMode Ltd. has a 12 month low of $13.68 and a 12 month high of $19.85. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of 6.14 and a beta of 2.02.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The firm had revenue of $77.87 million for the quarter, compared to the consensus estimate of $82.21 million. During the same period in the prior year, the business earned $0.32 EPS. The company's quarterly revenue was down 3.0% compared to the same quarter last year. Equities analysts expect that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.